GlassScriptPhysician profile
Bunnie Jo Hill
NPI 1316946023
$1,420.70
in general payments reported to CMS, 2019-2025
15 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.31 · 2020: $299 · 2021: $322 · 2022: $72.51 · 2023: $194 · 2024: $94.33 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.32 | 2021-2025 | |
| Amarin Pharma, INC. | $269.63 | 2019-2022 | |
| Amgen INC. | $147.00 | 2020-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $97.14 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.76 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.54 | 2019-2024 | Trintellix |
| Abbott Laboratories | $65.54 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $64.12 | 2020-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $42.33 | 2020 | |
| Lilly USA, LLC | $35.90 | 2025 | Kisunla, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.18 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $19.87 | 2021 | |
| Pfizer INC. | $16.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.01 | 2021 | |
| Seqirus USA INC | $13.89 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bunnie Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.